The levels of sMUC-1 in patients with multiple myeloma

Folia Histochemica et Cytobiologica

Volumn 49, Issue 4, 2011, Pages 654-658

  Lemancewicz, Dorota ^a   Bolkun, Lukasz ^a   Porowska, Halina ^a   Galar, Marzenna ^a   Semeniuk, Janusz ^a   Kloczko, Janusz ^a   Dzieciol, Janusz ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Multiple myeloma; sMUC 1

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE; MUCIN 1; SOLUBLE MUCIN 1; THALIDOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL;

EID: 84856786147     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0089     Document Type: Article

References (32)

1. Patton S, Gendler SJ, Spicer AP. The epithelial mucin, Muc1, of milk, mammary gland and other tissues. Biochim Biophys Acta. 1995;1241:407-424.
2. McGuckin MA, Hurst TG, Ward BG. Heterogeneity in production, secretion, and glycosylation of Muc1 epithelial mucin by primary cultures of ovarian carcinoma. Int J Cancer. 1995;63:412-418.
3. Burchell J, Gendler S, Taylor-Papadimitriou J et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987;47:5476-5482.
4. Porowska H, Paszkiewicz-Gadek A, Lemancewicz D, Bielawski T, Wolczynski S. Effect of brefeldin A on membrane localization of MUC1 mucin and adhesive properties of cancer cells. Neoplasma. 2008;55:305-311.
5. Vizcarra E, Lluch A, Cibrian R et al. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res Treat. 1996;37:209-216.
6. Cramer DW, Titus-Ernstoff L, McKolanis JR et al. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1125-1131.
7. Hayes DF, Sekine H, Ohno T et al. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest. 1985;75:1671-1678.
8. Takahashi T, Makiguchi Y, Hinoda Y et al. Expression of Muc1 on myeloma cells and induction of HLA unrestricted CTL against Muc1 from a multiple myeloma patient. J Immunol. 1994;153:2102-2109.
9. Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific MHC unrestricted recognition of tumor associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA. 1989;86:7159-7163.
10. Ioannides CG, Fisk B, Jerome KR et al. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol. 1993;151:3693-3703.
11. Hayes DF, Silberstein DS, Rodrique SW, Kufe DW. DF3 antigen, a human epithelial cell mucin, inhibits adhesion of eosinophils to antibody coated targets. J Immunol. 1990;145:962-970.
12. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ et al. Episialin (Muc1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol. 1993;151:767-776.
13. Irimura T, McIsaac AM, Carlson DA et al. Soluble factor in normal tissues that stimulates high-molecular-weight sialoglycoprotein production by human colon carcinoma cells. Cancer Res. 1990;50:3331-3338.
14. Fujita K, Denda K, Yamamoto M et al. Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients. B Cancer. 1999;80:301-308.
15. Teoh G, Chen L, Urashima M et al. Adenovirus vector based purging of multiple myeloma cells. Blood. 1998; 92:4591-601.
16. Croce CM. Oncogenes and cancer. N Engl J Med. 2008;358: 502-511.
17. Li Y, Liu D, Chen D, Kharbanda S, Kufe D. Human DF3/ /MUC1 carcinoma-associated protein functions as an oncogene. Oncogene. 2003;22:6107-6110.
18. Moniaux N, Chaturvedi P, Varshney GC et al. Human MUC4 mucin induces ultrastructural changes and tumorigenicity in pancreatic cancer cells. Br J Cancer. 2007;97:345-357.
19. Bafna S, Singh AP, Moniaux N, Eudy JD, Meza JL, Batra SK. MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res. 2008;68:9231-9238.
20. Wei X, Xu H, Kufe D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell. 2005;7:167-178.
21. MacLean GD, Reddish MA, Longenecker BM. Prognostic significance of preimmunotherapy serum CA27.29 (MUC1) mucin level after active specific immunotherapy of metastatic adenocarcinomas patients. J Immunother. 1997;20:70-79.
22. Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol. 1998,102: 1115-1123.
23. Radziejewska I, Borzym-Kluczyk M, Namiot Z, Stefanska E. Glycosylation of mucins present in gastric juice: the effect of helicobacter pylori eradication treatment. Clin Exp Med. 2011;11:81-88.
24. Paydas S, Sahin B, Gonlusen G, Hazar B, Zorludemir S. MUC1 expression in plasmacytoma. Leuk Res. 2001;25:221-225.
25. Takahashi T, Makiguchi Y, Hinoda Y et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol. 1994;153:2102-2109.
26. Luminari S, Goldaniga M, Ceccherelli F et al. Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias. Br J Haematol. 2003;121:772-774.
27. Treon SP, Mollick JA, Urashima M et al. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood. 1999;93:1287-1298.
28. Durum SK, Aiello FB. Interleukin-7 induces MUC1. Cancer Biol Ther. 2003;2:194-195.
29. Mileshkin L, Prince HM, Seymour JF, Biagi JJ. Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide. Br J Haematol. 2003;123:747-748.
30. Treon SP, Shima Y, Grossbard ML et al. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Ann Oncol. 2000; 11:107-111.
31. Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 2010;29:2893-2904.
32. Noto H, Takahashi T, Makiguchi Y et al. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int Immunol. 1997;9:791-798.